TrialJournal of immunology research2015

Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.

Shigeru Yutani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.